Altimmune, Inc. (NASDAQ: ALT) priced a $225 million underwritten public offering on April 22, 2026, selling 64.25 million shares of common stock and accompanying warrants, plus an additional 10.75 million shares of pre‑funded warrants and warrants. The offering was fully oversubscribed, underscoring strong investor demand for the company’s late‑stage liver‑disease program.
The gross proceeds of $225 million, before underwriting discounts and fees, will be directed toward funding the company’s upcoming Phase 3 metabolic dysfunction‑associated steatohepatitis (MASH) trial for pemvidutide, supporting working capital, and general corporate purposes. The financing is expected to close on or about April 24, 2026, and is projected to extend Altimmune’s runway into 2028, positioning the company to advance pemvidutide toward regulatory approval.
Prior to the offering, Altimmune’s cash, cash equivalents, and short‑term investments stood at $274 million as of December 31, 2025, rising to approximately $340 million by February 28, 2026, after a $75 million offering in January 2026. The new capital injection further strengthens the balance sheet and provides the liquidity needed to sustain late‑stage development milestones.
Investors reacted negatively to the announcement, citing dilution risk from the issuance of new shares and warrants and uncertainty surrounding the completion of the offering. The market’s concern reflects the typical trade‑off between capital infusion and shareholder dilution in biotech financing events.
Management emphasized the strategic importance of the raise. In a prior statement, President and CEO Jerry Durso noted that “this investment is an important step in strengthening Altimmune’s balance sheet and increasing our operational and strategic flexibility as we move toward initiation of our Phase 3 trial.” The new funding aligns with that objective by ensuring sufficient resources to pursue pemvidutide’s clinical development and potential market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.